331857-03-5

Upstream product

• 2365-48-2 Methyl thioglycolate 
• 147992-80-1 2-chloro-4-(dimethylamino)nicotinonitrile 
• 14164-26-2 α-Cyano-β-dimethylaminocrotononitrile 
• 91945-90-3 2-[1,3-bis(dimethylaminoallylidene)]malononitrile 
• 872889-89-9 C₁₁H₁₃N₃O₂S 

Downstream Products

• 159583-14-9 3-(4-Chloro-phenyl)-9-dimethylamino-3H-pyrido[3',2':4,5]thieno[3,2-d]pyrimidin-4-one 
• 159583-12-7 3,4-dihydro-3-benzyl-9-dimethylaminopyrido-<3,2:4',5'>thieno<3,2-d>pyrimidin-4-one 
• 159583-15-0 9-Dimethylamino-3-p-tolyl-3H-pyrido[3',2':4,5]thieno[3,2-d]pyrimidin-4-one 
• 159583-13-8 9-dimethylamino-3-phenyl-3H-pyrido[3',2':4,5]thieno[3,2-d]pyrimidin-4-one 

Relevant academic research and scientific papers

FUSED TRICYCLIC MGLUR1 ANTAGONISTS AS THERAPEUTIC AGENTS

In its many embodiments, the present invention provides tricyclic compounds of formula I (wherein J1-J3, X, Z, and R1-R4 are as defined herein) useful as metabotropic glutamate receptor (mGluR) antagonists, part

Fused tricyclic mGIuR1 antagonists as therapeutic agents

In its many embodiments, the present invention provides tricyclic compounds of formula I (wherein J1-J3, X, Z, and R1, R3, and R4 are as defined herein) useful as metabotropic glutamate receptor (mGlu

ANTAGONISTS OF THE MGLU RECEPTOR AND USES THEREOF

The present invention discloses compounds of general formula (I) wherein X1-X4 and R1-R3 are as defined in the description. The present invention also discloses methods of treatment for pain, neurodegeneration and convulsive states in a host mammal in need thereof, and pharmaceutical compositions including those compounds.

mGluR1 antagonists as therapeutic agents

In its many embodiments, the present invention provides tricyclic compounds of formula I (wherein J1-J4, X, and R1—R5 are as defined herein) useful as metabotropic glutamate receptor (mGluR) antagonists, particularly as selective metabotropic glutamate receptor 1 antagonists, pharmaceutical compositions containing the compounds, and methods of treatment using the compounds and compositions to treat diseases associated with metabotropic glutamate receptor (e.g., mGluR1) such as, for example, pain, migraine, anxiety, urinary incontinence and neurodegenerative diseases such Alzheimer's disease.

Structure-activity relationship of triazafluorenone derivatives as potent and selective mGluR1 antagonists

SAR (structure-activity relationship) studies of triazafluorenone derivatives as potent mGluR1 antagonists are described. The triazafluorenone derivatives are non-amino acid derivatives and noncompetitive mGluR1 antagonists that bind at a putative alloste